
#News: Today’s FDA approval of a treatment for pediatric patients age 12+ with moderate to severe #HidradenitisSuppurativa (#HS) marks a major step forward for this patient population.
Learn more about how Novartis is pioneering change in Immunology:
🔗 bit.ly/47jEn6v
English












